Lasonil Pain Relief 10% Bayer Anti-inflammatory Gel 120g

Lasonil Pain Relief 10% Bayer Anti-inflammatory Gel

Lasonil Anti Pain Gel 10% is used in the local treatment of bruises, sprains, myalgias, muscle strains, stiff necks, it is the ideal partner when situations arise that can cause joint and muscle pain.

This product is very useful both for athletes who can use it in case of injury and for problems related to injuries caused in everyday life, also excellent for those suffering from back problems.

Composition

Lasonil Pain Relief Gel 10% contains:
Active ingredient: Ibuprofen lysine salt 10 g
Excipients: Methyl sodium para-oxybenzoate, ethyl para-oxybenzoate sodium.

Dosage and method of use

The application of the product is very simple, 2-4 applications per day are recommended on the painful part, for elderly patients they should follow the minimum dosages indicated above, just apply a thin layer of gel on the part to be treated with a light circular massage until absorption, use the medicine for the shortest period possible, wash your hands thoroughly and prolonged after application.

Contraindications

• Hypersensitivity to the active substance or to any of the excipients.
• Due to the possibility of cross-sensitization, the medicinal product should not be administered to patients in whom acetylsalicylic acid or other non-steroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations.
• Pregnancy.
• Feeding time
• Children and adolescents under the age of 14.

Special warnings

It is advisable to avoid the application of Lasonil Antidolore in correspondence of open wounds or skin lesions. The use of Lasonil Antidolore, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. The administration of Lasonil Antidolore should be discontinued in women who have fertility problems or who are undergoing fertility investigations. The use of Lasonil Antidolore, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, interrupt the treatment and adopt adequate therapeutic measures.

To avoid more serious phenomena of hypersensitivity or photosensitivity, the patient must not expose himself to direct sunlight, including the solarium, during the treatment and in the following two weeks. In the event of allergic reactions or major adverse reactions (skin reactions, some of them fatal, such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis) therapy must be discontinued immediately. Patients appear to be at higher risk in the early stages of therapy: the onset of skin reactions occur in most cases within the first month of treatment. Do not use Lasonil Antidolore together with another NSAID or, in any case, do not use more than one NSAID at a time.

Pregnancy and breastfeeding

The use of Lasonil Antidolore is contraindicated in pregnancy and breastfeeding. Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was considered to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause increased pre- and post-implantation loss and embryo / fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals given prostaglandin synthesis inhibitors during the organ genetic period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can exhibit:

• the fetus with cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension), renal dysfunction, which can progress to renal failure with oligo-hydroamnios;
• the mother and the newborn, at the end of pregnancy, a possible prolongation of the bleeding time, and an antiplatelet effect which can occur even at very low doses and inhibition of uterine contractions resulting in delay or prolongation of labor.

Expiry and Retention

It is important to see the expiry date shown on the package, no special attention is required for product storage, the important thing is to keep the product out of reach of children, store in a dry place away from sources of heat and humidity, it is important the expiry date refers to the unopened product, it is important not to use the medicine after the expiry date indicated on the package.

Format

120g tube ready to use.